NHS England has published NHS performance statistics for February, which show that the service is continuing to struggle under pressure.
NHS England has published NHS performance statistics for February, which show that the service is continuing to struggle under pressure.
Researchers have announced a study to identify new treatments for uveal melanoma.
Merck has announced an AI-based collaboration with Iktos.
As many as 38% of NHS bodies such as clinical commissioning groups (CGCs) and hospital trusts are failing to show that the money they spend is good value, according to a report by the Public Accounts Committee.
King’s College London and The Chinese University of Hong Kong have renewed their long-standing partnership but also agree to work on mental health as part of the collaboration.
A new study has warned that the use of disinfectants to clean and control infections in hospitals should be regulated in the same way that prescribing antibiotics is, to help combat antimicrobial resistance.
MSD’s anti-PD-1 therapy Keytruda has been approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of adults with metastatic squamous non-small cell lung cancer (NSCLC).
Adults in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) have won early access to Roche’s immunotherapy Tecentriq in combination with nab-paclitaxel chemotherapy.
The European Commission has approved Roche and Chugai Pharma UK’s Hemlibra for the prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors, expanding the drug’s treatment scope.
Following on from the success of last year’s 25th anniversary, the prestigious PharmaTimes Marketer of the Year competition is now open for entry – continuing it’s role as a benchmark for marketing excellence.
Novo Nordisk presents ‘Ozempic’ interface at eyeforpharma conference in Barcelona.
MSD highlights the importance of digital transformation at the eyeforpharma conference in Barcelona.
The delivery of healthcare is still organised to predominantly serve the needs of providers and staff rather than patients, hear delegates at the eyeforpharma conference in Barcelona.
Following a meeting with the executive steering group, PharmaTimes is delighted to announce the finalists for this year’s immensely popular International Clinical Researcher of the Year competition.
Lilly is gearing up to file Cyramza for first-line treatment of certain lung cancer patients, after new trial data showed that the drug significantly extended progression-free survival (PFS) in this setting.